Jaguar Health — Third Quarter 2026 Earnings Summary
Jaguar Health reported a net loss of $5.8 million for the third quarter of 2026, a significant improvement from the $9.6 million loss in the same period the previous year. The company reduced its outstanding debt balance by $10.1 million during the quarter and recognized $1.8 million in holdback payments from its exclusive U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1. Total net revenue for the quarter was $2.3 million, driven primarily by license and grant revenue, while prescription product revenue declined to approximately $0.5 million following the transfer of U.S. commercial rights to Future Pak. Jaguar continues to focus its resources on the development of a powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, with a New Drug Application filing for microvillus inclusion disease planned for mid-2027.
- Company
- JAGUAR HEALTH INC
- Sector
- Healthcare
- Industry
- Biotechnology